Acute reboxetine administration increases plasma and salivary cortisol.
J Psychopharmacol
; 17(3): 273-5, 2003 Sep.
Article
en En
| MEDLINE
| ID: mdl-14513918
We investigated the effect of a single oral dose of the selective noradrenaline reuptake inhibitor, reboxetine (4 mg), on plasma and salivary cortisol in 24 healthy volunteers in a randomized, placebo-controlled, parallel-group design. Reboxetine significantly increased both plasma and salivary cortisol, although the correlation between the responses in plasma and saliva was modest. Our results are consistent with previous neuroendocrine challenge studies showing that potentiation of brain noradrenaline function stimulates the hypothalamic-pituitary-adrenal axis. Reboxetine-induced salivary cortisol release appears to be a simple and relatively non-invasive test of hypothalamic noradrenaline function. However, placebo-controlled, within-subject designs are likely to yield a more valid measure of noradrenaline-mediated cortisol release.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Saliva
/
Hidrocortisona
/
Morfolinas
/
Inhibidores de Captación Adrenérgica
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Psychopharmacol
Asunto de la revista:
PSICOFARMACOLOGIA
Año:
2003
Tipo del documento:
Article
Pais de publicación:
Estados Unidos